Latest PARP inhibitor Stories
RnRMarketResearch.com adds “Market Research Report on Global and Chinese Olaparib (CAS 763113-22-0) Industry, 2009-2019” Latest Report to its store. Dallas,
SAN FRANCISCO, Nov.
Sales of Breast Cancer Therapies are Expected to Almost Double Through 2023, Fueled by Growth in Several Distinct Market Segments, According to Findings from Decision Resources Group BURLINGTON,
Presentations include first Phase 2 results evaluating investigational compound Veliparib in patients with non-small cell lung cancer NORTH CHICAGO, Ill., Sept.
Women with mutations in the PALB2 gene have on average a one in three chance of developing breast cancer by the age of seventy.
Around a quarter of smokers who carry a defect in the BRCA2 gene will develop lung cancer at some point in their lifetime.
The Most Promising Emerging Agents in Development for Triple Negative Breast Cancer Target Only Specific Patient Subsets, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Today we know that women carrying BCRA1 and BCRA2 gene mutations have a 43% to 88% risk of developing from breast cancer before the age of 70.
The Jeffrey Epstein VI Foundation backs the FDA's landmark decision to approve inhibitor cocktails for melanoma. NEW YORK, Feb.